Clinical trials: Neurocognitive Disorders, Mild
Alzheimer's Disease
A Non-drug Methods Study in Participants With Alzheimer's Disease
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs…
- Trial name
- NCT01459016
- Testing
- PET scan using florbetapir, MRI Scan
- Where
- 16 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Mild Alzheimer's Disease
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment.
- Trial name
- NCT01548287
- Testing
- AZD5213
- Where
- 13 sites in United States
- Volunteers
- 164 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment
Efficacy and Safety Study of Shenwu Capsule
The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are…
- Trial name
- NCT01451749
- Testing
- Shenwu Capsule, Donepezil
- Where
- China
- Volunteers
- 324 people
- Sponsor
- North China Pharmaceutical Group Corporation
Alzheimer's Disease
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD.
- Trial name
- TANGO (NCT03352557)
- Testing
- BIIB092
- Where
- 101 sites in United States, Australia and 7 more
- Volunteers
- 654 people
- Sponsor
- Biogen
Mild Cognitive Impairment
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01434667
- Testing
- APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- Brigham and Women's Hospital
Sedentary Lifestyle, Dementia, Mild
Smartphone App to Improve Physical Activity in Older Adults With MCI/Mild Dementia
The purpose of this study is to develop and test a physical activity-tracking smartphone app designed to facilitate physical activity in older adults with mild cognitive impairments or mild dementia.
- Conditions
- Sedentary Lifestyle, Dementia, Mild, Mild Cognitive Impairment, Memory and Thinking Problems
- Trial name
- NCT04950998
- Testing
- Moving Up - A
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Alzheimer's Disease
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00710684
- Testing
- SB-742457 15mg, SB-742457 35mg, donepezil 5-10mg
- Where
- 102 sites in United States, Argentina and 7 more
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Down Syndrome, Mild Cognitive Impairment
Nicotine Treatment of Cognitive Decline in Down Syndrome
This study will ascertain whether nicotine is safe and tolerable in DS patients, help with dose-ranging of nicotine in DS, look for evidence of enhancements in cognitive functioning, and establish evidence for biological and…
- Trial name
- NCT01778946
- Testing
- Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Mild Cognitive Impairment
Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)
This is an administrative supplement to an existing project "Using fMRI-guided TMS to increase central executive function in older adults: NCT02767323" This award allows extending our existing fMRI-TMS paradigm to patients with a…
- Trial name
- MCI_Sub (NCT04176406)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Duke University
Aging, Mild Cognitive Impairment
Internet-based Conversational Engagement Clinical Trial
The study aims to randomize 320 (160 Caucasian, 160 African American) socially isolated adults 75+ years old (50:50 split between those with normal cognition and mild cognitive impairment (MCI)) recruited from the community to…
- Trial name
- I-CONECT (NCT02871921)
- Testing
- Conversational Engagement
- Where
- 2 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Late Onset Alzheimer
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly.
- Trial name
- NINDS-AIREN (NCT02007291)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Late Onset Alzheimer Disease
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline.
- Trial name
- NCT01222351
- Testing
- BAY 94-9172 (Florbetaben)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- New York State Psychiatric Institute
Dementia, Cognitive Impairment
5-Cog Battery for Detecting Cognitive Impairment and Dementia
Despite the availability of numerous cognitive assessment tools, cognitive impairment related to dementia is frequently under-diagnosed in primary care settings.
- Conditions
- Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurocognitive Disorders
- Trial name
- 5-Cog (NCT03816644)
- Testing
- 5-Cog, Health Literacy & Grip Assessment
- Where
- United States
- Volunteers
- 1,201 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Parkinson's Disease, Mild Cognitive Impairment
Mild Cognitive Impairment in Parkinson's Disease
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease.
- Trial name
- NCT01519271
- Testing
- Exelon Patch (rivastigmine transdermal system)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Depression
Prevention of Depression in Spouses of People With Cognitive Impairment
This study evaluates the effectiveness of a problem-solving training program in preventing depression in the spouses or family caregivers of persons with mild cognitive impairment or early dementia.
- Trial name
- NCT00321971
- Testing
- PST-MCI/AD Caregiving, NT-MCI/AD Caregiving
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.
- Trial name
- NCT00428090
- Testing
- Rosiglitazone
- Where
- 138 sites in United States, Austria and 18 more
- Volunteers
- 862 people
- Sponsor
- GlaxoSmithKline